Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1998 Nov;89(11):1179–1186. doi: 10.1111/j.1349-7006.1998.tb00513.x

Characterization of a Human Small‐cell Lung Cancer Cell Line Resistant to a New Water‐soluble Camptothecin Derivative, DX‐8951f

Taisuke Nomoto 1,2, Kazuto Nishio 1,✉, Tomoyuki Ishida 1, Masatomo Mori 2, Nagahiro Saijo 1
PMCID: PMC5921713  PMID: 9914787

Abstract

DX‐8951f, a water‐soluble and non‐pro‐drug analogue of camptothecin, exhibits a strong inhibitory action on DNA topoisomerase I (Topo I) and in vitro cytotoxicity against various human cancer cell lines. In order to elucidate the mechanisms of its cytotoxicity, we established a DX‐8951f‐resistant cell line, SBC‐3/DXCL1, from human small cell lung cancer cells (SBC‐3) by stepwise exposure to DX‐8951f. SBC‐3/DXCL1 cells were approximately 400 times more resistant to DX‐8951f than parent cells. The SBC‐3/DXCL1 cells showed a high degree of cross‐resistance to other Topo I inhibitors such as CPT‐11, SN‐38 and camptothecin, but not to non‐Topo I targeting agents such as cisplatin, adriamycin, etoposide, and vincristine. The mechanisms of resistance of SBC‐3/DXCL1 cells to DX‐8951f were examined. Intracellular accumulation of DX‐8951f by SBC‐3 and SBC‐3/DXCL1 cells did not differ significantly. Although the Topo I activity of nuclear extracts obtained from SBC‐3/DXCL1 cells was the same as that of the parent cells, the Topo I of SBC‐3/DXCL1 cells was resistant to the inhibitory effects of DX8951f and SN‐38. Immunoblotting using anti‐Topo I antibody demonstrated similar protein levels of Topo I in SBC‐3 and SBC‐3/DXCL1 cells. The active Topo I protein of SBC‐3/DXCL1 was eluted by a high concentration of NaCl (0.4 N) compared with that of SBC‐3 (0.3 N). DX‐8951f stabilized the DNA‐Topo I cleavable complex from SBC‐3 cells, as measured by Topo I‐mediated cleavage assay. In SBC‐3/DXCL1 cells, DX‐8951f also stabilized the DNA‐Topo I complex, but with a 10‐fold lower efficiency. These results suggest that a qualitative change in Topo I contributes, at least partially, to the resistance to DX‐8951f in SBC‐3/DXCL1 cells. Therefore, SBC‐3/DXCL1 cells may have a unique mechanism of resistance to Topo I‐directed antitumor drugs.

Keywords: DX‐8951f, Drug‐resistance, Topoisomerase I, Lung cancer, Camptothecin

Full Text

The Full Text of this article is available as a PDF (386.6 KB).

REFERENCES

  • 1. ) Wang , J. C.DNA topoisomerase Annu . Rev. Biochem. , 65 , 635 – 692 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) Chen , A. Y. and Liu , L. F.Topoisomerases: essential enzymes and lethal targets . Annu. Rev. Biochem. , 34 , 191 – 218 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 3. ) D'Arpa , P. , Beardmore , C. and Liu L. F.Involvement of nucleic acid synthesis in cell killing mechanisms of Topo poisons . Cancer Res. , 50 , 6919 – 6924 ( 1990. ). [PubMed] [Google Scholar]
  • 4. ) Hsiang , Y.‐H. , Hertzberg , R. , Hecht , S. and Liu , L. F.Camptothecin induces protein‐linked DNA breaks via mammalian DNA Topo I . J. Biol. Chem. , 260 , 14873 – 14878 ( 1985. ). [PubMed] [Google Scholar]
  • 5. ) Kaneda , N. , Nagata , H. , Furuta , T. and Yokokura , T.Metabolism and pharmacokinetics of the camptothecin analogue CPT‐11 in the mouse . Cancer Res. , 50 , 1715 – 1720 ( 1990. ). [PubMed] [Google Scholar]
  • 6. ) Kingsbury , W. D. , Boehm , J. C. , Jakas , D. R. , Holden , K. G. , Hecht , S. M. , Gallagher , G. , Caranfa , M. J. , McCabe , F. L. , Faucette , L. F. , Johnson , R. K. and Hertzberg , R. P.Synthesis of water‐soluble (aminoalkyl) camptothecin analogues: inhibition of Topo I and antitumor activity . J. Med. Chem. , 34 , 98 – 107 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 7. ) Giovanella , B. C. , Stehlin , J. S. , Wall , M. E. , Wani , M. C. , Nicholas , A. W. , Liu , L. F. , Silber , R. S. and Potmesil , M.DNA Topo I targeted chemotherapy of human colon cancer in xenografts . Science , 246 , 1046 – 1048 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 8. ) Fukuoka , M. , Niitani , H. , Suzuki , A. , Motomiya , M. , Hasegawa , K. , Nishiwaki , Y. , Kuriyama , T. , Ariyoshi , Y. , Negoro , S. , Masuda , N. , Nakajima , S. and Taguchi , T.A phase II study of CPT‐11, a new derivative of camptothecin, for previously untreated non‐small‐cell lung cancer . J. Clin. Oncol. , 10 , 16 – 20 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 9. ) Ohno , R. , Okada , K. , Masaoka , T. , Kuramoto , A. , Arima , T. , Yoshida , Y. , Ariyoshi , H. , Ishimaru , M. , Sakai , Y. , Oguro , M. , Ito , Y. , Morishima , Y. , Yokomaku , S. and Ota , K.An early of CPT‐11, for the treatment of leukemia and lymphoma . J. Clin. Oncol. , 8 , 1907 – 1912 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 10. ) Taguchi , T. , Makui , A. and Hasegawa , K.Phase I clinical study of CPT‐11 . Jpn. J. Cancer Chemother. , 17 , 115 – 120 ( 1990. ) ( in Japanese ). [PubMed] [Google Scholar]
  • 11. ) Mitsui , I. , Kumazawa , E. , Hirota , Y. , Aonuma , M. , Sugimori , M. , Ohsuki , S. , Uoto , K. , Ejima , A. , Terasawa , H. and Sato , K.A new water‐soluble camptothecin derivative, DX‐8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo . Jpn. J. Cancer Res. , 86 , 776 – 782 ( 1995. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. ) Creemers , G. J. , Lund , B. and Verweij , J.Topoisomerase I inhibitors: topotecan and irinotecan . Cancer Treat. Rev. , 20 , 73 – 96 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 13. ) Potmesil , M.Camptothecins: from bench research to hospital wards . Cancer Res. , 54 , 1431 – 1439 ( 1994. ). [PubMed] [Google Scholar]
  • 14. ) Pommier , Y. , Tanizawa , A. , Okada , K. and Andoh , T.Cellular determinants of sensitivity and resistance to camptothecins . In“Camptothecins: New Anticancer Agents ,” ed. Potmesil M. and Pinedo H. , pp. 123 – 138 ( 1995. ). CRC Press; , Boca Raton . [Google Scholar]
  • 15. ) Mosmann , T.Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays . J. Immunol. Methods , 65 , 55 – 63 ( 1983. ). [DOI] [PubMed] [Google Scholar]
  • 16. ) Tsuruo , T. , Iida‐Saito , H. , Kawabata , H. , Oh‐hara , T. , Hamada , H. and Utakoji , T.Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and in isolated clones . Jpn. J. Cancer Res. , 77 , 682 – 692 ( 1986. ). [PubMed] [Google Scholar]
  • 17. ) Horichi , N. , Tapiero , H. , Sugimoto , Y. , Bungo , M. , Nishiyama , M. , Fourcade , A. , Lampidis , T. J. , Kasahara , K. , Sasaki , Y. , Takahashi , T. and Saijo , N.3′‐Deamino‐3′‐morpholino‐13‐deoxo‐10‐hydroxycarminomycin conquers multidrug resistance by rapid influx following higher frequency of formation of DNA single‐ and double‐strand breaks . Cancer Res. , 50 , 4698 – 4701 ( 1990. ). [PubMed] [Google Scholar]
  • 18. ) Deffie , A. M. , Batra , J. K. and Goldenberg , G. J.Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin‐sensitive and ‐resistant P388 leukemia cell lines . Cancer Res. , 49 , 58 – 62 ( 1989. ). [PubMed] [Google Scholar]
  • 19. ) Liu , L. F. and Miller , K. G.Eukaryotic DNA topoisomerases: two forms of type I DNA topoisomerases from HeLa cell nuclei . Proc. Natl. Acad. Sci. USA , 78 , 3487 – 3491 ( 1981. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. ) Ogasawara , H. , Nishio , K. , Kanzawa , F. , Lee , Y.‐S. , Funayama , Y. , Ohira , T. , Kuraishi , Y. , Isogai , Y. and Saijo , N.Intracellular carboxyl esterase activity is a determinant of cellular sensitivity to the antineoplastic agent KW‐2189 in cell lines resistant to cisplatin and CPT‐11 . Jpn. J. Cancer Res. , 86 , 124 – 130 ( 1995. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. ) Emerson , D. L. , Besterman , J. M. , Brown , H. R. , Evans , M. G. , Leitner , P. P. , Luzzio , M. J. , Shaffer , J. E. , Sternbach , D. D. , Uehling , D. and Vuong , A.In vivo anti‐tumor activity of two new seven‐substituted water‐soluble camptothecin analogues . Cancer Res. , 55 , 603 – 609 ( 1995. ). [PubMed] [Google Scholar]
  • 22. ) Mattern , M. R. , Hofmann , G. A. , Polsky , R. M. , Funk , L. R. , McCabe , F. L. and Johnson , R. K.In vitro and in vivo effects of clinically important camptothecin analogues on multidrug‐resistant cells . Oncol. Res. , 5 , 467 – 474 ( 1993. ). [PubMed] [Google Scholar]
  • 23. ) Kijima , T. , Kubota , N. and Nishio , K.Establishment of a CPT‐11‐resistant human ovarian cancer cell line . Anticancer Res. , 14 , 799 – 803 ( 1994. ). [PubMed] [Google Scholar]
  • 24. ) Jansen , W. J. , Zwart , B. , Hulscher , S. T. , Giaccone , G. , Pinedo , H. M. and Boven , E.CPT‐11 in human colon‐cancer cell lines and xenografts: characterization of cellular sensitivity determinants . Int. J. Cancer , 70 , 335 – 340 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 25. ) Goldwasser , F. , Bae , I. , Valenti , M. , Torres , K. and Pommier , Y.Topoisomerase I‐related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute antitumor screen . Cancer Res. , 55 , 2116 – 2121 ( 1995. ). [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES